The Burzynski Clinic, Houston, Texas, USA
Case Report
Unusually long survival (over 33 years) observed in 61 high-grade glioma patients treated in phase II studies of Antineoplastons A10 and AS2-1
Author(s): Stanislaw R. Burzynski*, Tomasz J. Janicki, Gregory S. Burzynski, Radoslaw J. Siwiec and Samuel W. Beenken
Background: High-Grade Gliomas (HGGs) are among the most aggressive and deadly primary brain tumors. Standard treatment includes surgery, external beam radiation and temozolomide, which can cause marked toxicity. Despite intensive therapy, the prognosis remains poor.
Objective: To assess long-term outcomes and safety in non-Glioblastoma (non-GBM) HGG patients treated with Antineoplastons A10 and AS2-1 (ANP) at the Burzynski Clinic (BC) under phase II protocols.
Methods: Sixty-one non-GBM HGG patients received intravenous ANP. Eligibility required Karnofsky/Lansky Performance Scores (KPS/LPS) of at least 60 and a life expectancy of at least 2 months. ANP was administered via a subclavian catheter and automated pump. Maximum tolerated doses of A10 and AS2-1 were achieved. Outcomes included objective response, surviva.. View More»
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 